Investigational breast cancer vaccine plus immune therapy work well in tandem
(Duke University Medical Center) A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at Duke Cancer Institute is part of an effective, two-drug strategy for enlisting the immune system to fight tumors, according to a Duke-led study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | HER2 | Study | Vaccines